<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101696</url>
  </required_header>
  <id_info>
    <org_study_id>16-024</org_study_id>
    <nct_id>NCT03101696</nct_id>
  </id_info>
  <brief_title>Determination of Coronarphysiological Parameters With the Method of Thermodillution</brief_title>
  <official_title>Determination of Coronarphysiological Parameters With the Method of Thermodillution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gold standard to induce coronary hyperemia for measurement of fractional flow reserve&#xD;
      (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) is&#xD;
      adenosine, but it exerts several side effects due to its unspecific action on adenosine&#xD;
      receptors. The specific A2a-receptor agonist, regadenoson, has been shown to dilate coronary&#xD;
      arteries and enables FFR measurements. The aim of the study was to evaluate whether&#xD;
      simultaneous measurement of FFR, CFR and IMR is feasible, safe and effective within&#xD;
      regadenoson-induced hyperemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fractional flow reserve (FFR), coronary flow reserve (CFR) and the index of microcirculatory&#xD;
      resistance (IMR) provide significant information on the conductance of coronary macro- and&#xD;
      microcirculation.&#xD;
&#xD;
      FFR-based functional assessment of coronary artery disease has proven to be superior to&#xD;
      purely morphologic assessment and thereby guides therapy decision. IMR is a&#xD;
      pressure-temperature derived parameter for quantifying microcirculatory resistance, which has&#xD;
      been proven to be relatively independent of epicardial stenosis severity when taking&#xD;
      collateral flow into account. IMR is increased in patients with acute myocardial infarction&#xD;
      and microvascular obstruction (MVO) as assessed by contrast-enhanced CMR and predicts left&#xD;
      ventricular function and enddiastolic volumes at 6 month independently of initial infarct&#xD;
      size.&#xD;
&#xD;
      Most interestingly, even in the absence of obstructive coronary artery disease, IMR is&#xD;
      elevated in more than 20% of patients presenting with chest pain. The clinical meaning for&#xD;
      this finding has to be elucidated.&#xD;
&#xD;
      FFR, CFR and IMR can only be measured under conditions of minimal coronary resistance with&#xD;
      the need for coronary hyperemia. The current &quot;gold standard&quot; to induce hyperemia in the&#xD;
      assessment of coronary conductance is adenosine. However, adenosine is known to cause side&#xD;
      effects (bronchospasm and disturbances in atrioventricular conduction) due to its unselective&#xD;
      action on all adenosine receptors. Besides that, adenosine requires a body weight adapted&#xD;
      dosing and continuous infusion. However, alternative routes like intracoronary injection show&#xD;
      good correlation compared with the intravenous route and side effects can be reduced. In&#xD;
      contrast, regadenoson, a specific A2A receptor agonist, exhibits negligible side effects. It&#xD;
      can be administered intravenously as a non-body weight adapted bolus via peripheral vein&#xD;
      without the need for transfemoral delivery. Thus, patients with a transradial access for&#xD;
      cardiac catheterization might benefit the most from inducing hypermedia via peripheral vein.&#xD;
      It has already been shown that regadenoson increases coronary blood flow yielding comparable&#xD;
      values for FFR and indexes of perfusion in SPECT. However, the duration and stability of&#xD;
      regadenoson-induced hyperemia might be insufficient for a simultaneous measurement of FFR,&#xD;
      CFR and IMR, which has not been tested so far.&#xD;
&#xD;
      The aim of the present study is to evaluate whether simultaneous measurement of the&#xD;
      parameters FFR, CFR and IMR under regadenoson-induced hyperemia is feasible, safe and&#xD;
      effective in patients with stable coronary artery disease undergoing a transradial procedure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2017</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fractional flow reserve (FFR)</measure>
    <time_frame>Baseline</time_frame>
    <description>Description: the proximal aortic (Pa) and distal arterial pressure (Pd) are recorded and RadiAnalyzer Xpress™ control unit automatically calculates FFR as Pd/Pa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>coronary flow reserve</measure>
    <time_frame>Baseline</time_frame>
    <description>The RadiAnalyzer Xpress™ calculates CFR as Tmnr/Tmnh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>index of microcirculatory resistance</measure>
    <time_frame>Baseline</time_frame>
    <description>Using the derived Pd and transit mean times under hyperemia (Tmnh), it will be calculated apparent IMR as Pd×Tmnh. All IMR values are also corrected by Yong's formula (IMRcorr=Pa×Tmnh×([1.35×Pd/Pa]-0.32) to adjust for the influence of collateral flow.</description>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Coronary Artery Stenosis of Unclear Hemodynamic Relevance</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with indication for FFR measurement due to a coronary artery stenosis of unclear&#xD;
        hemodynamic relevance&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Coronary angiography with indication of FFR measurement&#xD;
&#xD;
          -  angiography without pathological results explaining the patients' symptoms&#xD;
&#xD;
          -  intermediate stenosis (50-70%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Hypersensitivity towards regadenoson&#xD;
&#xD;
          -  hemodynamic instability&#xD;
&#xD;
          -  severe hypotension&#xD;
&#xD;
          -  acute myocardial ischemia&#xD;
&#xD;
          -  AV block II-III&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Malte Kelm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiology, Pulmonary Disease and Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Dr. med. Florian Bönner</investigator_title>
  </responsible_party>
  <keyword>coronary angiography</keyword>
  <keyword>coronary conductance</keyword>
  <keyword>hyperemia</keyword>
  <keyword>regadenoson</keyword>
  <keyword>fractional flow reserve</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>index of microcirculatory resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

